EADV 2026

FOSTER CITY, Calif. — September 28, 2026 Sagimet Biosciences Inc. announced that it will host a virtual key opinion...

PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...

Waltham, Massachusetts, U.S., September 21, 2026 Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory...

WATERTOWN, Mass., Sept. 1, 2026 Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class...

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...